Quality of life in venous disease

Korlaar, Inez van; Vossen, C. Y.; Rosendaal, Frits R.; Cameron, Linda D.; Bovill, Edwin G.; Kaptein, Adrian A.

doi:10.1055/s-0037-1613595

Cited by 87 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Khan et al reported that DVT effect on QOL is noticeable years after the event 6. Van Korlaar et al noted that the decrease in QOL is related to symptom severity and development of PTS 7. In addition, Lubberts et al performed a large meta-analysis to assess health-related QOL in patients with DVT with at least one year of reported symptoms 8.…”

Section: Epidemiology Symptoms and Quality Of Life Of Patients With mentioning

confidence: 99%

<p>Iliac vein compression: epidemiology, diagnosis and treatment</p>

Radaideh¹,

Patel²,

Shammas³

2019

VHRM

View full text Add to dashboard Cite

Iliac vein compression (LIVC) is a prevalent finding in the general population, but a smaller number of patients are symptomatic. ILVC should be considered in symptomatic patients with unexplained unilateral lower leg swelling. Patients typically complain of one or more of the following symptoms: lower leg pain, heaviness, venous claudication, swelling, hyperpigmentation and ulceration. ILVC can be thrombotic, combined with acute or chronic DVT, or non-thrombotic. ILVC is best diagnosed with intravascular ultrasound (IVUS), but computed tomography angiography (CTA) and magnetic resonance angiography (MRA) have emerged as valid screening tests. Venography underestimates the severity of ILVC but may provide insights into the anatomy and the presence of collaterals. Based on current available evidence, endovascular therapy with stenting remains the main treatment strategy for ILVC. Dedicated nitinol venous stents are currently under review by the Food and Drug Administration for potential approval in the United States. These stents have been released outside the US. There is no consensus to the optimal anticoagulation regimen post-ILVC stenting. Oral anticoagulants, however, remain a preferred therapy in patients with history of thrombotic ILVC.

show abstract

Section: Epidemiology Symptoms and Quality Of Life Of Patients With mentioning

confidence: 99%

<p>Iliac vein compression: epidemiology, diagnosis and treatment</p>

Radaideh¹,

Patel²,

Shammas³

2019

VHRM

View full text Add to dashboard Cite

show abstract

“…The VEINES-QoL/Sym questionnaire specifically assesses quality of life and symptoms of a range of conditions in chronic venous disorders of the leg [10]. SF-36 is a generic QoL tool measuring health across three dimensions and including eight separate scales: functional status (physical functioning, social functioning, role limitations attributed to physical problems, and role limitations attributed to emotional problems), wellbeing (including mental health, energy and fatigue, and pain) and overall evaluation of health (including general health perception) [11]. Adverse events were also collected: major adverse events were defined as postoperative complications requiring admission or surgery and minor adverse events as postoperative complications requiring only medical treatment or monitoring (e.g., bruising, skin disorders, pain, puncture-site infection).…”

Section: Data Collectionmentioning

confidence: 99%

Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study

Falvo¹,

Latreche²,

Chevallier³

et al. 2023

Preprint

View full text Add to dashboard Cite

Endovenous thermal methods are superseding surgical stripping for treating chronic superficial venous disease but require tumescent anesthesia and can cause heat-related nerve injuries. Endovenous cyanoacrylate ablation is a more recent technique that does not share these drawbacks. Retrospective observational study of consecutive adults managed with endovenous cyanoacrylate in 2018–2021 at a single university center. Follow-up was 18 months. We identified factors associated with target vein closure at 18 months and measured changes in quality of life using the generic 36-item Short-Form tool (SF-36) and the venous disease-specific VEINES-QOL/Sym questionnaire. Adverse events were collected. In the 55 study patients with 67 treated veins, the closure rate at 18 months was 94% (95%CI, 85%–98%). Target vein diameter ≥9.5 mm had 81% sensitivity and 75% specificity for predicting recanalization. Both quality-of-life scores improved significantly (P&lt;0.001 for both). The only adverse event was a type IV allergic reaction to cyanoacrylate that resolved with corticosteroid and histamine-antagonist therapy. Endovenous cyanoacrylate ablation was highly effective and safe in experienced hands. Studies are warranted to determine whether changes in the protocol increase the closure rate in patients with target veins ≥9.5 mm in diameter.

show abstract

“…The VEINES-QoL/Sym questionnaire specifically assesses the quality of life and symptoms of a range of conditions in chronic venous disorders of the leg [10]. The SF-36 is a generic QoL tool measuring health across three dimensions and including eight separate scales: functional status (physical functioning, social functioning, role limitations attributed to physical problems, and role limitations attributed to emotional problems), wellbeing (including mental health, energy and fatigue, and pain) and overall evaluation of health (including general health perception) [11]. Adverse events were also collected: major adverse events were defined as postoperative complications requiring admission or surgery and minor adverse events as postoperative complications requiring only medical treatment or monitoring (e.g., bruising, skin disorders, pain, puncture-site infection).…”

Section: Data Collectionmentioning

confidence: 99%

“…A total of 32 GSV and 35 SSV were treated. The mean size (mm) of the treated veins was 8.5± 2.4 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16).…”

Section: Patients and Target Veinsmentioning

confidence: 99%

Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study

Falvo¹,

Latreche²,

Chevallier³

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Endovenous thermal methods are superseding surgical stripping for treating chronic superficial venous disease but require tumescent anesthesia and can cause heat-related nerve injuries. Endovenous cyanoacrylate ablation is a more recent technique that does not share these drawbacks. A retrospective observational study of consecutive adults managed with endovenous cyanoacrylate was conducted in 2018–2021 at a single university center. The follow-up was 18 months. We identified factors associated with target vein closure at 18 months and measured changes in quality of life using the generic 36-item Short-Form (SF-36) tool and the venous disease-specific VEINES-QOL/Sym questionnaire. Adverse events were collected. In the 55 study patients with 67 treated veins, the closure rate at 18 months was 94% (95% CI, 85–98%). Target vein diameter ≥9.5 mm had 81% sensitivity and 75% specificity for predicting recanalization. Quality-of-life scores improved significantly (p < 0.001 for both surveys). The only adverse event was a type IV allergic reaction to cyanoacrylate that was resolved with corticosteroid and histamine-antagonist therapy. Endovenous cyanoacrylate ablation was highly effective and is safe in experienced hands. Studies are warranted to determine whether changes in the protocol increase the closure rate in patients with target veins ≥9.5 mm in diameter.

show abstract

Quality of life in venous disease

Cited by 87 publications

References 20 publications

<p>Iliac vein compression: epidemiology, diagnosis and treatment</p>

<p>Iliac vein compression: epidemiology, diagnosis and treatment</p>

Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study

Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study

Contact Info

Product

Resources

About